Briviact Briviact is the brand name for brivaracetam, an antiepileptic drug (AED) approved for adjunctive treatment of partial‑onset seizures in patients ≥2 years old. It is a highly selective synaptic vesicle protein 2A (SV2A) ligand that modulates presynaptic neurotransmitter release. — Mechanism of Action High‑affinity SV2A modulation: Brivaracetam binds to SV2A with ~25‑30‑times higher affinity than … Read more
Briumvi Briumvi (tirzepatide) is a once‑weekly, subcutaneous dual agonist of the glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP) receptors. It is approved for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with ≥ 1 weight‑related comorbidity. Mechanism of Action Dual receptor agonist: activates both GLP‑1 and GIP receptors, amplifying insulin secretion and … Read more
Brimonidine Mechanism of Action Brimonidine is a selective α₂‑adrenergic receptor agonist. Binding: Stimulates pre‑ and post‑synaptic α₂‑receptors in ocular tissues. Effects: ↓ Intraocular pressure (IOP) by reducing aqueous humor production through decreased cAMP in ciliary epithelium. ↑ Outflow via enhancement of uveoscleral and trabecular meshwork drainage. Peripheral vasoconstriction reduces conjunctival hyperemia (common feature of glaucoma … Read more
Brilinta (ticagrelor) Mechanism of Action Brilinta (ticagrelor) is a rapid‑acting, reversible P2Y12 ADP receptor antagonist. Binds competitively to the purinoreceptor on platelet surfaces, prevents ADP‑induced activation and aggregation. Unlike thienopyridines, it does not require hepatic ½‑life metabolic activation; active drug is present immediately after absorption. Provides a stable, predictable antiplatelet effect with a short half‑life … Read more
Breztri Aerosphere Breztri Aerosphere is a once‑daily inhaled combination of the corticosteroid fluticasone furoate and the long‑acting β2‑agonist vilanterol delivered via a metered‑dose inhaler (MDI)/aero‑sphere. It is approved for maintenance therapy of chronic obstructive pulmonary disease (COPD) and asthma when a dual‑action inhaler is preferred. — Mechanism of Action Fluticasone furoate: Potent glucocorticoid that binds mineralocorticoid receptors, … Read more
Breyanzi _Breyanzi_ (idecabtagene vicleucel) is an autologous, CD19‑targeted CAR‑T cell therapy approved for the treatment of relapsed or refractory (R/R) large B‑cell lymphoma (LBCL) in adults who have received at least four lines of systemic therapy. Mechanism of Action Engineering: Patient’s peripheral blood T cells are harvested (apheresis) and transduced ex vivo with a lentiviral vector … Read more
Brexpiprazole Brexpiprazole (brand name Rexulti) is a third‑generation antipsychotic with a unique pharmacological profile. It serves as a partial agonist at dopamine D₂/D₃ and serotonin 5‑HT₁A receptors, with a moderate antagonist effect at 5‑HT₂A receptors. Approved by the FDA for the adjunctive and monotherapy treatment of schizophrenia and as monotherapy for depressive episodes in major … Read more
Breo Ellipta Breo Ellipta (fluticasone furoate / vilanterol) is a once‑daily, dry‑powder inhaled corticosteroid (ICS) + long‑acting β₂‑agonist (LABA) combination used for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). — Mechanism of Action Fluticasone furoate High‑potency glucocorticoid → binds mineralocorticoid‑free glucocorticoid receptors in airway smooth‑muscle and alveolar macrophages. Suppresses transcription of pro‑inflammatory cytokines (IL‑4/5/13, IL‑8), reduces eosinophil recruitment, and diminishes … Read more
Botox Botox is a licensed formulation of purified abobotulinum toxin type A used for both therapeutic and aesthetic purposes. It remains the most widely studied and prescribed botulinum toxin for a variety of neuromuscular disorders and cosmetic indications. Mechanism of Action Neuromuscular Blockade: Botulinum toxin type A cleaves SNAP‑25, a SNARE protein essential for acetylcholine … Read more
Boniva Mechanism of Action Boniva (ibandronate sodium) is a bisphosphonate that selectively attaches to hydroxyapatite in bone, inhibiting osteoclast‑mediated bone resorption. Binding: The nitrogen‑containing heterocycle and carboxylate groups bind strongly to bone mineral surfaces, especially at sites of active remodeling. Inhibition of Osteoclasts: By altering farnesyl pyrophosphate synthase activity, ibandronate impairs prenylation of small GTPase … Read more